ScholarIQanswers from OpenAlex

Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction

PaperCitations, authors & open-access status

Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction have?

ScholarIQcitation count

Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction has 49 citations in the OpenAlex counts ScholarIQ stores.

When was Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction published?

ScholarIQyear

Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction has 2010 year in the ScholarIQ index.

What is the open-access status of Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction?

ScholarIQoa status

Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction has closed oa status in the ScholarIQ index.

What is the DOI of Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction?

ScholarIQdoi

The DOI for Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction is on the source record.

What is the PMID of Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction?

ScholarIQpmid

The PMID for Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction is on the source record.

What is the OpenAlex record for Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction?

ScholarIQopenalex

The OpenAlex for Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial